Article

Malalignment and cartilage lesions in the patellofemoral joint treated with autologous chondrocyte implantation

Molecular Cell Biology and Regenerative Medicine, Sahlgrenska University Hospital, Gothenburg University, Gothenburg, Sweden.
Knee Surgery Sports Traumatology Arthroscopy (Impact Factor: 2.84). 03/2011; 19(3):452-7. DOI: 10.1007/s00167-010-1267-1
Source: PubMed

ABSTRACT The aim of our current study is to present the 12.6 years' follow-up results in patients with cartilage lesions of the patellofemoral joint, treated with autologous chondrocyte implantation (ACI) with the use of periosteum.
Ninety-two patients having patella or trochlea lesion participated in this study. Lysholm and Tegner questionnaires were completed 12.6 years (SD 2.3 years) after the surgery. The patients were asked whether they feel better, worse or had not experienced any difference compared to previous years and whether they would undergo the operation again. Complications or subsequent surgeries were also assessed.
Median Tegner score was three, improved by one level compared with preoperative values (P = 0.02). Median Lysholm score was 70, improved by nine points (n.s.). Seventy-two percent of the patients were better or unchanged while 93% would undergo the operation again. Patients with no kissing lesions appeared to have a better prognosis. Patients with malalignment or instability that had undergone a realignment procedure had comparable outcomes to the patients that did not need any additional surgery. Realignment procedures increased the incidence of serious complications but they were associated with decreased incidence of periosteal hypertrophy. No association was found between the age of the patients at the time of the ACI or the size per lesion and any of the clinical outcomes.
ACI provides a satisfactory outcome for the treatment of cartilage lesions of the patellofemoral joint, even for the cases with concomitant patellar instability. It seems that correcting the coexisting background factors with realignment, stabilizing or unloading procedures, along with the treatment of cartilage lesions, is improving the clinical outcomes over time and decreases the incidence of periosteal hypertrophies although increasing the incidence of serious complications. Our study reveals the good results and the high level of patients' activities (as shown by Tegner score), were preserved 12.6 years after the implantation, in both isolated trochlea and patella lesions and also in multiple and in kissing lesions where an intervention could be considered as a salvage procedure.

1 Follower
 · 
115 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Cartilage defects of the patellofemoral joint represent different entities. Results of patellofemoral cartilage repair are often variable. Concomitant pathologies, such as malalignment and instability are frequent. Currently no common treatment concept exists. Improvement of patellofemoral biomechanics, e.g. tubercle transfer, results in better outcome independent of the cartilage repair technique used. In patellofemoral instability reconstruction of the medial patellofemoral ligament (MPFL) has recently become a focus of interest. Microfracturing and osteochondral cylinder transfer/mosaicplasty are recommended for smaller defects, while comparative studies have shown advantages for autologous chondrocyte implantation (ACI) in defects larger than 4 cm². In our study patients with patellofemoral scaffold ACI (MACI®), better Lysholm scores were seen with isolated trochlea defects rather than patella defects or bipolar lesions. While trochlea defects can be effectively addressed, treatment of bipolar patellofemoral defects by scaffold ACI cannot generally be recommended. Follow-up treatment of the patellofemoral joint is more time and cost-consuming than other defect localizations. For the development of therapeutic algorithms further well-defined large randomized studies are necessary.
    Der Orthopäde 09/2011; 40(10):885-8, 890-5. · 0.67 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Patellofemorale Knorpelschäden stellen keine ätiologische Entität dar. Komorbiditäten wie Malalignement oder Instabilität sind häufig. Die Ergebnisse patellofemoraler Knorpeloperationen sind variabel. Die aktuelle Studienlage lässt kein einheitliches Therapiekonzept erkennen: Tendenziell bessere Ergebnisse können verfahrensübergreifend durch eine Verbesserung der Biomechanik wie z.B. dem Tuberositastransfer erzielt werden. Bei patellofemoraler Instabilität tritt die Rekonstruktion des medialen patellofemoralen Ligaments (MPFL) verstärkt in den Interessenfokus. Mikrofrakturierung oder osteochondraler Zylindertransfer bzw. Mosaikplastik werden eher für kleinere Defekte empfohlen. Für Defektgrößen ab 4cm2 zeigen komparative Studien Vorteile für die autologe Chondrozytentransplantation (ACT). Bei unseren eigenen Patienten schnitten nach einer Matrix-ACT (MACI®) die isolierten Trochleadefekte vor den Patelladefekten und den bipolaren Läsionen im Lysholm-Score am besten ab. Während Trochleadefekte effektiv therapierbar sind, kann eine ACT bei bipolaren Läsionen nicht uneingeschränkt empfohlen werden. Die Nachbehandlung patellofemoraler Läsionen geht mit einem erhöhten Bedarf an Zeit und Ressourcen einher. Weitere klar definierte komparative randomisierte Studien mit größeren Fallzahlen sind für die Entwicklung eines differenziellen Therapiealgorithmus notwendig. Cartilage defects of the patellofemoral joint represent different entities. Results of patellofemoral cartilage repair are often variable. Concomitant pathologies, such as malalignment and instability are frequent. Currently no common treatment concept exists. Improvement of patellofemoral biomechanics, e.g. tubercle transfer, results in better outcome independent of the cartilage repair technique used. In patellofemoral instability reconstruction of the medial patellofemoral ligament (MPFL) has recently become a focus of interest. Microfracturing and osteochondral cylinder transfer/mosaicplasty are recommended for smaller defects, while comparative studies have shown advantages for autologous chondrocyte implantation (ACI) in defects larger than 4cm2. In our study patients with patellofemoral scaffold ACI (MACI®), better Lysholm scores were seen with isolated trochlea defects rather than patella defects or bipolar lesions. While trochlea defects can be effectively addressed, treatment of bipolar patellofemoral defects by scaffold ACI cannot generally be recommended. Follow-up treatment of the patellofemoral joint is more time and cost-consuming than other defect localizations. For the development of therapeutic algorithms further well-defined large randomized studies are necessary. SchlüsselwörterPatellofemoralgelenk–Knorpelschaden–Realignement–Mikrofrakturierung–Autologe Chondrozytentransplantation (ACT) KeywordsPatellofemoral joint–Cartilage defect–Realignment–Microfracturing–Autologous chondrocyte implantation (ACI)
    Der Orthopäde 10/2011; 40(10):885-895. DOI:10.1007/s00132-011-1776-8 · 0.67 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The 3-dimensional autologous chondrocyte transplantation (ACT3D) comprises isolation of chondrocytes from cartilage biopsies, cultivation to spheroids, and transplantation into the cartilage defect. To evaluate the patients' general health and functionality and to assess the defect repair after ACT3D with spheroids by MRI and MOCART scoring. Thirty-seven patients with isolated chondral lesions of the knee underwent ACT3D with spheroids through medial arthrotomy. Patient-administered scores were assessed at baseline (day before transplantation), at 6 weeks, and at 3, 6, and 12 months. MRI and MOCART scoring were performed at 3 and 12 months after ACT3D. Patients were diagnosed with full-thickness patellofemoral (n = 16), femoral condylar (n = 18), or both defect types (n = 3), International Cartilage Repair Society (ICRS) grade 3 or 4, with defect sizes between 1.0 and 12.0 cm(2). On average, 59.5 spheroids/cm(2) in defect size were transplanted. An overall statistically significant improvement from baseline to 12 months was observed for all assessment scores (Lysholm, International Knee Documentation Committee [IKDC], SF-36, Tegner) combined with a significant reduction in the visual analog scale (VAS) for pain and an advanced defect filling. Subgroup analyses revealed a positive clinical outcome independent on defect size, defect locations, spheroid dosage, age, duration of symptoms, and severity of complaints at baseline. Seven patients experienced in total 8 adverse events, of which knee joint effusion and blocking were assessed as possibly or probably related to ACT3D. The patient-administered assessment scores along with the fast defect filling with ACT3D using spheroids demonstrated an increase in activity level and quality of life after a 1-year follow-up.
    Cartilage 01/2012; 3(1):pp. 27-42. DOI:10.1177/1947603511417616